Vivera Pharmaceuticals Partners with Areum Bio LLC and Access Bio, Inc. to Expand the National Distribution of Emergency Use Authorized COVID-19 Rapid Tests
Retrieved on:
Wednesday, June 30, 2021
The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.
Key Points:
- The efficiency of the EUA-authorized point of care (POC) CareStart Rapid Antigen Test, coupled with Vivera's broad distribution capabilities, will ensure the greater ease of access to rapid diagnostic testing solutions.
- The distribution partnership between Vivera, Areum Bio, and Access Bio will help make rapid testing more readily available as quickly as possible.
- "This co-branded collaboration marks a new strategic alliance for Vivera," said Paul Edalat, Chairman and CEO of Vivera Pharmaceuticals.
- "This is a great opportunity for Areum Bio to partner with Vivera, a reputable pharmaceutical company, for the nationwide distribution of the CareStart COVID-19 Rapid Antigen Tests," said Dr. Jong Kim, President of Areum Bio.